Alloy Therapeutics, Inc.’s Post

I’m excited to share another update on our technical roadmap. Thanks to our strategic collaboration and license agreement with Takeda, we will be able to support our partners with proprietary iCAR-T and iCAR-NK platforms. During my last trip to Japan, I was able to experience firsthand the amazing quality of the scientific work taking place at the Kyoto University and other institutions. Creating a new subsidiary in Japan will enable our R&D team to accelerate our innovation taking advantage of the best ideas and practices coming from our highly diverse team. We started with transgenic mouse technology for antibody discovery, but during the last few years quickly expanded our offering to solutions for drugging HLA/peptide complexes, novel antisense oligonucleotide platform soon to include more related modalities. Our team is working hard on new delivery technologies. In this context we are welcoming the opportunity to support innovation with new solutions for cell therapies.  

A new and valuable platform for Alloy enabling patients to access cost effective iPSC CAR-T cell therapies for the treatment of cancer

What if doctors could turn T-cells “on” and “off” to better manage the severe side effects that affect some recipients of CAR-T therapies? AvenCell Therapeutics is developing a CAR-T platform that would do just that. Their platform integrates a universal chimeric antigen receptor on engineered T-cells with a targeting molecule that guides T-cells to cancer antigens. This allows T-cells to be switched on or off at will, opening the therapeutic window to help doctors manage safety and efficacy challenges for today’s therapies.  CAR-T therapies stand out as an example of a brilliant innovation that hasn’t quite lived up to its potential yet. Developments like this one should remind us to embrace optimism about our industry’s ability to solve even the most complex scientific challenges.  #CellAndGene #Pharma #Oncology https://lnkd.in/dHqq2XJe  

Calico Biosystems gets the CHF 150,000 Kick to predict drug efficacy in cancer patients. Read the full article: https://lnkd.in/e8aiaa5m Congrats to Co-Founders CEO Marie-Agnès Doucey and CSO Riccardo Turrini and their whole team! About: Both the high attrition rate (> 95%) of drugs and the low response rate of patients to approved anti-cancer therapies call for a game changer in therapeutic testing. Calico Biosystems merges innovative experimental and digital approaches to assess the potency of therapeutics on patient tumors. The experimental approach uses the exclusive know-how of the founders in testing therapeutics on native patient tumors. The digital approach, based on computational modeling, predicts the most potent combinations of therapeutics to benefit patients in the clinic. The founders are former Unil collaborators with more than 10 years of experience in systems immuno-oncology. Calico Biosystems is poised to become the leader of Precision Oncology in a market estimated to reach 500B USD by 2030. #VentureKick #SwissStartups

🚀 The Antibody-Drug Conjugates (ADC) market is poised for significant growth, driven by increasing demand for targeted cancer therapies. With advancements in technology and expanding pipelines, ADCs are revolutionizing oncology treatments by offering enhanced precision in targeting tumor cells, while minimizing damage to healthy tissues. #ADCmarket #antibodydrugconjugates #globaldata

Roche has acquired Poseida Therapeutics, Inc. Therapeutics in a $𝟏.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐝𝐞𝐚𝐥, marking a major step in its cell therapy ambitions. This move strengthens Roche's focus on off-the-shelf CAR-T therapies, aiming to make advanced treatments more accessible. Poseida, known for its cutting-edge technology and promising blood cancer programs, will bring its innovative pipeline under Roche's wing. This acquisition reflects Roche's growing investment in cell therapies following their initial partnership in 2022. Exciting developments are ahead for democratizing access to life-changing treatments! https://lnkd.in/emDpizWp #BiotechNews #CellTherapy #CAR_T #m&a

The fight against #cancer is more crucial now than ever before, and Noble is at the forefront of developing preclinical platforms for screening potential anticancer treatments. 🔬Using the CellTiter-Glo Luminescence Cell Viability Assay, we are able to quickly and effectively assess the #efficacy of drug candidates in inhibiting cancer cell growth. Together, we can improve the success rate of new therapeutics and ultimately save lives. 💜 Discover our expertise in the white paper, In Vitro Tumor Cell Model Systems for Anticancer Drug Screening and Verification: https://ow.ly/4pky50QTouu #cancerresearch #anticancertreatment #innovation #oncology #researchanddevelopment

Once IPO-bound, the market's sway redirected Obsidian Therapeutics Therapeutics course. Today, thanks to a remarkable $160.5M funding round led Madan Jagasia, lays out the next chapter with a fresh Series C infusion poised for clinical advancements. 🧬 The FDA's nod for Lifileucel, first of its-kind TIL therapy for solid tumours, paves the way for novel treatments. Obsidian Therapeutics' cutting-edge cytoDRiVE® technology has the potential to reshape cancer care with its unique approach to regulated protein function tackling malignancies like metastatic melanoma and non-small cell lung cancer. OBX-115, a tailored T-cell marvel, holds promise for the hard-hit, showcasing how pharmacologically adjustable proteins can redefine healing. #Biotechnology #ClinicalTrials #SeriesCFunding #ObsidianTherapeutics #CellTherapy #TIL #ElixirAssociates

𝐅𝐥𝐚𝐫𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐑𝐨𝐜𝐡𝐞 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐭𝐨 𝐓𝐚𝐫𝐠𝐞𝐭 𝐓𝐫𝐚𝐧𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐢𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 Flare Therapeutics Flare Therapeutics has announced a strategic discovery collaboration with Roche Roche to develop small molecule drugs for undrugged transcription factor targets in oncology. Leveraging Flare’s proprietary proteomic platform and Roche’s global oncology expertise, the partnership aims to address high-unmet medical needs with innovative therapies. Flare will receive a $70M upfront payment and is eligible for milestone payments exceeding $1.8B, plus royalties. The company will lead discovery and preclinical efforts, while Roche will focus on clinical development and commercialization. Flare retains ownership of its existing pipeline, including its lead program FX-909 in advanced urothelial cancer. “This collaboration reflects a shared commitment to overcoming the challenges of drugging transcription factors and delivering breakthrough therapies for patients,” said Rob Sims, Ph.D. Robert Sims, CSO of Flare Therapeutics. #FlareTherapeutics #Roche #OncologyInnovation #TranscriptionFactors #BiotechPartnership #CancerTherapies

The commercial success of second-generation #radiopharmaceuticals in #oncology has reignited interest in this transformative modality 🧬💡. Early #radiotherapies lacked potency and specificity. Scientists and clinicians persisted, linking radioactive isotopes to #tumor-targeting molecules. The result? Radiopharmaceuticals that hit the bullseye 🎯 This success lead to a surge of recent #licensing, #partnerships, #mergersandacquisitions and increased #venturecapital financing for companies in the field. #cancerresearch #precisionmedicine #precisiononcology #pharmainnovation #pharmaceuticalinnovation #biotechinnovation #dealmaking #preventativemedicine #predictiveanalytics #targetedtherapy https://lnkd.in/edrnUSjt